MX2010000937A - Tratamiento del trastorno por estrés postraumático. - Google Patents

Tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000937A
MX2010000937A MX2010000937A MX2010000937A MX2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A
Authority
MX
Mexico
Prior art keywords
post
stress disorder
traumatic stress
patient
compound
Prior art date
Application number
MX2010000937A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000937A publication Critical patent/MX2010000937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proveen métodos para tratar a un paciente a quien se le ha diagnosticado trastorno postraumático mediante la administración al paciente de una cantidad terapéuticamente efectiva de Compuesto A. También se proveen métodos para mejorar la respuesta de recuperación de un paciente mediante la administración de una cantidad terapéuticamente efectiva de Compuesto A. También se proveen métodos para diagnosticar el trastorno postraumático en un paciente mediante la administración al paciente de una cantidad terapéuticamente efectiva de Compuesto A, determinar al menos un signo, síntoma o conjunto de síntomas de trastorno por stress postraumático y diagnosticar trastorno por stress postraumático en el paciente si el Compuesto A reduce al menos un signo, síntoma o conjunto de síntomas de trastorno postraumático.
MX2010000937A 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático. MX2010000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000937A true MX2010000937A (es) 2010-06-25

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000937A MX2010000937A (es) 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090054403A1 (es)
EP (1) EP2182952A4 (es)
JP (1) JP2010534676A (es)
CN (1) CN101951912A (es)
AU (1) AU2008279091A1 (es)
CA (1) CA2707858A1 (es)
CO (1) CO6260078A2 (es)
MX (1) MX2010000937A (es)
NZ (1) NZ583193A (es)
RU (1) RU2458691C2 (es)
SG (1) SG183069A1 (es)
WO (1) WO2009015248A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101873799A (zh) * 2007-07-23 2010-10-27 辛诺西亚治疗公司 用于治疗创伤后应激障碍的4-羟基-4-甲基-哌啶-1-羧酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
SG183696A1 (en) * 2007-08-06 2012-09-27 Biotie Therapies Inc Medicaments comprising nepicastat for use in treating dependence on a substance
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
EP2501234B1 (en) * 2009-11-20 2017-09-13 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
EP2968992B8 (en) 2013-03-15 2020-01-15 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
CN107072968B (zh) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
KR20200015534A (ko) * 2017-05-30 2020-02-12 폴 지. 에머슨 스트레스 장애에서 호르몬 연쇄반응(hormonal cascade)을 조절하는 조성물 및 방법
US11284934B2 (en) * 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
EP3723860A1 (en) 2017-12-11 2020-10-21 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
US20220313647A1 (en) * 2019-07-25 2022-10-06 Tokyo University Of Science Foundation Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms
WO2024118912A1 (en) * 2022-11-30 2024-06-06 Blinklab Ltd Psychopharmacological system and method using eyelid tracking

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2005215775B2 (en) * 2004-02-13 2011-02-03 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
US20090111817A1 (en) * 2005-07-06 2009-04-30 Sepracor Inc. Combinations of Eszopiclone and an Antidepressant
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
US20090054414A1 (en) * 2007-07-23 2009-02-26 Synosia Therapeutics Rufinamide for the Treatment of Post-Traumatic Stress Disorder

Also Published As

Publication number Publication date
CO6260078A2 (es) 2011-03-22
JP2010534676A (ja) 2010-11-11
CA2707858A1 (en) 2009-01-29
EP2182952A1 (en) 2010-05-12
CN101951912A (zh) 2011-01-19
NZ583193A (en) 2012-05-25
SG183069A1 (en) 2012-08-30
EP2182952A4 (en) 2010-09-08
AU2008279091A1 (en) 2009-01-29
WO2009015248A1 (en) 2009-01-29
US20090054403A1 (en) 2009-02-26
RU2010106014A (ru) 2011-08-27
RU2458691C2 (ru) 2012-08-20

Similar Documents

Publication Publication Date Title
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
MX2009012307A (es) Tratamiento de sinucleinopatias.
MX2010006823A (es) Metodos para el tratamiento de la gota.
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
WO2013033657A3 (en) CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
NZ603717A (en) Suture line administration technique using botulinum toxins
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
WO2006113900A3 (en) Methods and devices for relieving stress
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
IN2012DN00549A (es)
NZ611614A (en) Compositions and methods for treating amyloid plaque associated symptoms
NZ597115A (en) Method of treating age related disorders with fujimycin

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal